MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT)

Authors

Lone Heimann Larsen (ORCID: https://orcid.org/0000-0001-5639-4449)
Johan M. Burisch (ORCID: https://orcid.org/0000-0002-3312-5139)
Morten Lee Halling (ORCID: https://orcid.org/0000-0003-3610-6563)
Camilla Frimor
Charlotte Kloft (ORCID: https://orcid.org/0000-0001-9344-8514)
Mark Ainsworth (ORCID: https://orcid.org/0000-0002-4899-1048)
Ella Signe Kassandra Widigson
Casper Steenholdt
Jens Kjeldsen
Maiken Thyregod Joergensen

Institutions

University of Copenhagen (DK)
University of Southern Denmark (DK)
Aalborg University Hospital (DK)
Odense University Hospital (DK)
Hvidovre Hospital (DK)
Vejle Sygehus (DK)
Hospital South West Jutland (DK)
Predictive Science (United States) (US)
Freie Universität Berlin (DE)

Publication Details

Journal: BMJ Open Gastroenterology
Published: 2025-12-01
DOI: https://doi.org/10.1136/bmjgast-2025-001985
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Odense Universitetshospital

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT)

Lone Heimann Larsen, Johan M. Burisch, Morten Lee Halling, Camilla Frimor et al.

Dec 1, 2025

BMJ Open Gastroenterology

Inflammatory Bowel Disease

article

MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT)

Lone Heimann Larsen, Johan M. Burisch, Morten Lee Halling, Camilla Frimor, Charlotte Kloft, Mark Ainsworth, Ella Signe Kassandra Widigson, Casper Steenholdt, Jens Kjeldsen, Maiken Thyregod Joergensen

December 1, 2025article en

Abstract

No abstract available for this paper.

BMJ Open GastroenterologyVol. 12(1)

University of Copenhagen (DK), University of Southern Denmark (DK), Aalborg University Hospital (DK), Odense University Hospital (DK), Hvidovre Hospital (DK), Vejle Sygehus (DK), Hospital South West Jutland (DK), Predictive Science (United States) (US), Freie Universität Berlin (DE)

Odense Universitetshospital

Openalex Percentile: Top 25%

Inflammatory Bowel Disease

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT) — Lone Heimann Larsen, Johan M. Burisch, et al. · BMJ Open Gastroenterology (2025) | TGRS Research Map | TGRS